Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation

[EN]The immunosuppressive properties of mesenchymal stromal cells (MSC) have been successfully tested to control clinical severe graft-versus host disease and improve survival. However, clinical studies have not yet provided conclusive evidence of their efficacy largely because of lack of patients’...

Descripción completa

Detalles Bibliográficos
Autores: Trento, Cristina, Bernardo, Maria Ester, Nagler, Arnon, Kuçi, Selim, Bornhäuser, Martin, Köhl, Ulrike, Strunk, Dirk, Galleu, Antonio, Sánchez-Guijo Martín, Fermín, Gaipa, Giuseppe, Introna, Martino, Bukauskas, Adomas, Le Blanc, Katarina, Apperley, Jane, Roelofs, Helene, Van Campenhout, Ann, Beguin, Yves, Kuball, Jürgen, Lazzari, Lorenza, Avanzini, Maria Antonietta, Fibbe, Willem, Chabannon, Christian, Bonini, Chiara, Dazzi, Francesco
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2018
País:España
Institución:Universidad de Salamanca (USAL)
Repositorio:GREDOS. Repositorio Institucional de la Universidad de Salamanca
OAI Identifier:oai:gredos.usal.es:10366/146604
Acceso en línea:http://hdl.handle.net/10366/146604
Access Level:acceso abierto
Palabra clave:Mesenchymal stromal cells
Graft-versus-host disease
Cellular therapy
Manufacturing
Product specification
Release criteria
Mesenchymal Stromal Cells
Graft vs Host Disease
Hematology
3205.04 Hematología
enfermedad injerto contra huésped
hematología
células del estroma mesenquimatoso
Descripción
Sumario:[EN]The immunosuppressive properties of mesenchymal stromal cells (MSC) have been successfully tested to control clinical severe graft-versus host disease and improve survival. However, clinical studies have not yet provided conclusive evidence of their efficacy largely because of lack of patients’ stratification criteria. The heterogeneity of MSC preparations is also a major contributing factor, as manufacturing of therapeutic MSC is performed according to different protocols among different centers. Understanding the variability of the manufacturing protocol would allow a better comparison of the results obtained in the clinical setting among different centers. In order to acquire information on MSC manufacturing we sent a questionnaire to the European Society for Blood and Marrow Transplantation centers registered as producing MSC. Data from 17 centers were obtained and analyzed by means of a 2-phase questionnaire specifically focused on product manufacturing. Gathered information included MSC tissue sources, MSC donor matching, medium additives for ex vivo expansion, and data on MSC product specification for clinical release.

Similares en LA Referencia